NIPT Market in US Dominated by Sequenom

‘Although the current market is dominated by Sequenom, Ariosa is a player to watch out for’, says RNCOS.

 

Noida, UP -- (SBWIRE) -- 07/24/2015 -- The market for non-invasive prenatal diagnostic tests in the US is dominated by Sequenom, which has the first mover advantage in the market. With around 45% market share in terms of volume of tests, Sequenom boasts of having effective marketing strategies that seek to encourage US physicians to recommend its MaterniT21 plus test. Ariosa, a tough competitor to Sequenom with respect to volume of tests performed in 2014, accounted for second highest share in the NIPT market. In 2014, Ariosa Diagnostics captured a significant share of the NIPT market due to its wide accessibility across the United States.

According to our report, "US Non-Invasive Prenatal Testing Market Outlook 2020", the rise in high risk births has been contributing to the growth of the NIPT market which is anticipated to witness an impressive double digit growth in the next few years. This trend has been attributed to numerous factors such as recession and associated affordability issues and women being more career focused than before.

Our report provides a detailed insight into the current scenario and future outlook of the US NIPT market. The demographic scenario of United States has been discussed with focus on the current and future number of births, with the demographics segregated by age and state. Although, the market has witnessed stupendous growth and new tests have gained acceptance rapidly, much of it still remains untapped due to various reasons. This has been discussed in the section dedicated to the potential market for 2014 and 2020.

The US NIPT sector is characterized by the presence of players like Sequenom, Verinata, Ariosa and Natera. These players have been profiled with their strengths and weaknesses and latest developments in the field of NIPT. The report provides a prudent analysis of the current and future size of the market weighing the possible pessimistic and optimistic scenarios, is a must buy for players planning to enter the prenatal segment.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM755.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.